Brief: Bio-Path Holdings Announces First Patient Dosed In Phase 1 Clinical Trial Of Bp1002
19/11/2020 12:43
Nov 19 (Reuters) - Bio Path Holdings Inc BPTH.O :
* BIO-PATH HOLDINGS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1
CLINICAL TRIAL OF BP1002
* BIO PATH HOLDINGS INC - SIX EVALUABLE PATIENTS WILL BE
TREATED
WITH BP1002 MONOTHERAPY IN A STANDARD 3+3 DESIGN, WITH A
STARTING DOSE OF 20 MG/M
Source text for Eikon: ID:nGNXc7HS6d
Further company coverage: BPTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia